Summary
A survey among members of 16 Clinical Trials Committees and the Clinical Trials Evaluation Team of the Spanish Ministry of Health was carried out to discover their opinions about the procedure used to obtain informed consent in clinical research with drugs.
The responses of the 111 persons surveyed indicate that 97% consider that informed consent should be obtained before the patient is included in the trial, that it must “always” be in writing (68%), and that the consent form must previously have been approved by the Clinical Trials Committee (87%). The minimum information to be provided to the patient must be read by and later supplied to the subject (76%), and for at least 90% of the members surveyed it must “always” include: an invitation to participate in the clinical trial, information about the purpose, predictable benefits and risks of the trial, the statement that participation is voluntary and that refusal to participate would not imply loss of usual medical care, and that the trial was approved by the Clinical Trials Committee. Only 33% of those surveyed considered that the study design should “always” be described to the patient.
In order to find out what the general outlook on this issue is in Spain, it is necessary to perform studies among medical investigators and patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Real Decreto 944/1978, 14 de Abril de 1978. BOE, 6 de Mayo de 1978. Orden, Ministerio de Sanidad y Consumo, 3 de Agosto de 1982. BOE, 12 de Agosto de 1982.
Anon. (1988) Spain. Ethics Committees and Clinical Investigation. Lancet II: 676
Boletin Oficial de las Cortes Generales. Congreso de los Diputados. III Legislatura. Proyecto de Ley. 121/000112 Medicamento. Madrid, 17 de Marzo de 1989
Levine RJ (1986) Ethics and regulation of clinical research. 2nd ed. Urban and Schwarzenberg, Baltimore
Gerlis L (1989) Good Clinical Practice in clinical research. Lancet I: 1008–1009
Ministère des Affaires Sociales et de l'Emploi (1987) Bonnes Pratiques Cliniques. Avis aux promoteurs et aux investigateurs pour les essais cliniques des médicaments. Bulletin Officiel no 87–32 bis, Paris
FDA (1978) Department of Health, Education and Welfare. Obligations of clinical investigators of regulated articles. Fed Reg 43 (August 8th, Part V): 35210–35236
FDA (1981) Health and Human Services Department. Protection of human subjects: informed consent and standards for institutional review boards for clinical investigations. Fed Reg 46 (January 26th): 8942–8979
Ensayos Clínicos en España (1988) Serie Monografías Técnicas de la Dirección General de Farmacia y Productos Sanitarios, no 7. Ed Ministerio de Sanidad y Consumo, Madrid
Taylor KM, Kelner M (1987) Informed consent. The physician's perspective. Soc Sci Med 24: 135–143
Blum AL, Chalmers TC, Deutsch E, Koch-Weser J, Rosen A, Tygstrup N, Zentgraf R (1987) The Lugano statements on controlled clinical trials. J Int Med Res 15: 2–22
Cassileth BR, Zupkis RV, Sutton-Smith K, March V (1980) Informed consent. Why are its goals imperfectly realized? N Engl J Med 302: 896–900
Simes RJ, Tattersall MHN, Coates AS, Raghavan D, Solomon HJ, Smartt H (1986) Randomized comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. Br Med J 293: 1065–1068
Epstein LC, Lasagna L (1969) Obtaining informed consent. Arch Intern Med 123: 682–687
Riecken HW, Ravish R (1982) Informed consent to biomedical research in Veterans Administration Hospitals. JAMA 248: 344–348
McNeil BJ, Panker SQ, Sox HC, Tversky A (1982) On the elicitation of preferences for alternatives therapies. N Engl J Med 306: 1259–1262
Byrne P (1988) Medical Research and the human subject. Problems of consent and control in the UK experience. Ann NY Acad Sci 530: 144–153
Loi No 88-1138 du 20 décembre 1988 relative à la protection des personnes qui te pretent à des recherches biomédicales. Journal Officiel de la République Française, 22 décembre 1988: 16032–16035
Robertson JA (1982) IRB intervention in the consent process. IRB 4(5): 1–5
Herxheimer A (1988) The rights of the patient in clinical research. Lancet II: 1128–1130
Faden R, Lewis C, Rimer B (1980) Monitoring informed consent procedures: an explanatory record review. IRB 2 (8): 9–10
Bosso JA (1983) The role of the Institutional Review Board in Research involving human subjects. Drug Intell Clin Pharm 17: 828–834
Glover J (1986) The MRC and informed consent. Br Med J 293: 157–158
Brownell KD, Stunkard AJ (1982) The double-blind in danger. Untoward consequences of informed consent. Am J Psychiatry 139: 1487–1489
Moscussi M, Byrne L, Weintraub M, Cox C (1987) Blinding, unblinding and the placebo effect. An analysis of patients' guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther 41: 259–265
Myers MG, Carins JA, Singer J (1987) The consent form as a possible cause of side effects. Clin Pharmacol Ther 42: 250–253
Loftus EF, Fries JF (1979) Informed consent may be hazardous to health. Science 204: 11
Brewin TB (1985) Truth, trust and paternalism. Lancet II: 490–492
Baker MT, Taub HA (1983) Readability of informed consent forms for research in a Veterans Administration Medical Center. JAMA 250: 2646–2648
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dal-Ré, R. Informed consent in clinical research with drugs in Spain: Perspective of clinical trials committee members. Eur J Clin Pharmacol 38, 319–324 (1990). https://doi.org/10.1007/BF00315568
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315568